Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis
Someone with heart disease, for example, would be a poor candidate since relevant clinical trials havent met the primary endpoints for that use.29 Then there are people for whom SS-31 is contraindicated : women who are pregnant or breastfeeding, and people with a history of cancer
When BMAL1 levels are high, ECs demonstrate increased migration and tube formation, which accelerates BBB repair
Novo Nordisk filed a New Drug Application for the CagriSema combination (cagrilintide 2.4 mg + semaglutide 2.4 mg) in December 2025, with an FDA decision anticipated in late 2026
It also brings a natural glow to the skin, improving radiance and brightness
Cagrilintide has an extended elimination halflife reported in the range of approximately 159195 hours (about 78 days), supporting onceweekly subcutaneous dosing in clinical trials [1]